Skip to content
drillr.ai
Sign up

OLMA

Olema Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$7.11
+8.05%
Ask drillr

  • Oct 15, 2026, 21:07 UTC

    Olema Pharmaceuticals appointed Prakash Raman to its Compensation Committee and Science and Technology Committee, effective October 15, 2026.

  • Oct 15, 2026, 21:07 UTC

    Olema Pharmaceuticals director Gorjan Hrustanovic resigned from the board and its Compensation Committee and Science and Technology Committee, effective October 14, 2026.

  • Aug 13, 2026, 00:00 UTC

    Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.

  • Aug 11, 2026, 18:27 UTC

    Olema Pharmaceuticals completed enrollment in its pivotal Phase 3 OPERA-01 trial for breast cancer treatment, with top-line data expected in Q1 2027.

    Source: